AUGUST 2012
www.TheOncologyNurse.com
VOL 5, NO 7
CHILDHOOD CANCER
CANCER CENTER PROFILE
Secondary Neoplasms in Childhood Cancer Survivors
Columbia University Medical Center
By Louise Leuthner, RN, BSN Next Steps Clinic, Children’s Hospital of Wisconsin, HOT Services
Center for Lymphoid Malignancies
Lynnette Anderson, RN, MS, APNP Blood and Marrow Transplant Clinic, Next Steps Clinic, Children’s Hospital of Wisconsin Debra Schmidt, RN, MS, APNP Oncology Clinic, Next Steps Clinic, Children’s Hospital of Wisconsin Milwaukee, Wisconsin
T
here are a growing number of adults worldwide who are childhood cancer survivors. It is estimated that 80% of children diagnosed with cancer will be childhood cancer survivors and, as of 2005, there were 328,000
survivors of childhood cancer in the United States.1 As this population continues to grow in number and age, new challenges for these survivors emerge. Approximately two-thirds of childhood Continued on page 18
Ellen A. Neylon, MSN, FNP-BC, CCRP, OCN, is an oncology nurse practitioner at the Center for Lymphoid Malignancies, Columbia University Medical Center.
RENAL CELL CARCINOMA n March 2012, Columbia University announced the opening of the Center for Lymphoid Malignancies in New York City. The center’s focus is on the care of patients with the various forms of nonHodgkin lymphoma, chronic lymphocytic leukemia, acute lymphoblastic leukemia, and Hodgkin disease. The highly skilled and experienced staff at the center comprises more than 25 personnel, including physicians, nurses, clinical trial coordinators, regulatory specialists, laboratory scientists, and other support staff under the directorship of Owen A. O’Connor, MD, PhD. Although the healthcare professionals at the center are focused on lymphoid malignancies, they also have expertise in most hematologic cancers, including multiple myeloma, myelodysplastic syndrome, and acute myeloid leukemia. At the center, the emphasis is on research that translates the latest
I
Continued on page 17
Quality of Life Drives Patient Preference for Metastatic Renal Cell Carcinoma Drug By Wayne Kuznar
T
he surprising results of a randomized trial on patient preference for one cancer therapy over another show that patient-reported quality-of-life (QOL) differences influence treatment preference far more than physicians had imagined, suggested researchers at the
2012 Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois. In a double-blind, crossover trial, 169 patients with metastatic renal cell carcinoma (mRCC) were randomized 1:1 to 10 weeks of 800 mg of pazopanib or 50 Continued on page 22
CONFERENCE NEWS: MASCC
Advances in Supportive Care By Alice Goodman
A
t the recent 2012 symposium of the Multinational Association of Supportive Care in Cancer (MASCC), held in New York City, experts discussed a wide range of topics related to management of treatmentinduced side effects. Below are some highlights from the MASCC annual symposium.
INSIDE The PaTienT’s Voice . . . . . . . . . .
13
Broken-Down Me suPPorTiVe care
Management of Febrile Neutropenia Advances over the past few decades have led to reduced morbidity and mortality from chemotherapy-induced febrile neutropenia (FN). FN was once considered fatal, but in the modern era, mortality is about 5% and FN-related
Breathing Life Into Dyspnea Relief . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21 Nurse Practitioner–Delivered Automated Telephone Remote Monitoring System . . . . . 22
healTh insurance coVerage . . . . . . . . . . . . . . . . . . . . .
28
Provisions and Status of the Affordable Care Act BesT PracTices . . . . . . . . . . . . . .
30
Patient-Friendly Educational Book Enhances Transplant Process
You voted for the
ONE Award
Continued on page 8
FIND ©2012 Green Hill Healthcare Communications, LLC
OUT WHO WON ON PAGE
24